Atorvastatin for Inflammation in HIV

Phase 2, randomised, double-blind trial of atorvastatin in human immunodeficiency virus type 1 infection (HIV-1) (2 arms). Primary endpoints: Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in log10 IL-6, Difference Between [Change From Week 24 to Week 44] and [Change From Baseline to Week 20] in CD4+ T-cell Activation Percent and 2 more. Started Apr 2011; status: completed.